Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
Open Access
- 1 August 2021
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 58, 106-112
Abstract
No abstract availableKeywords
Funding Information
- NHMRC
- National Breast Cancer Foundation
- Australian Government Department of Industry Innovation and Science
- National Breast Cancer Foundation
This publication has 25 references indexed in Scilit:
- Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research StatementJournal of Clinical Oncology, 2017
- Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohortBMJ Open, 2017
- Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE StudyJournal of Clinical Oncology, 2017
- The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchersBMC Research Notes, 2015
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast CancerNew England Journal of Medicine, 2015
- Trastuzumab-containing regimens for metastatic breast cancerCochrane Database of Systematic Reviews, 2014
- Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancerCancer, 2014
- Randomised controlled trials and population-based observational research: partners in the evolution of medical evidenceBritish Journal of Cancer, 2014
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001